Akoustis Technologies Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akoustis Technologies in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Akoustis Technologies stock.
View analyst ratings for Akoustis Technologies or view top-rated stocks.

Wall Street analysts have given Akoustis Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Akoustis Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Akoustis Technologies saw a drop in short interest in the month of February. As of February 12th, there was short interest totaling 4,710,000 shares, a drop of 20.6% from the January 28th total of 5,930,000 shares. Based on an average daily volume of 979,300 shares, the days-to-cover ratio is currently 4.8 days.
View Akoustis Technologies' Short Interest.

Akoustis Technologies is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for Akoustis Technologies.

Akoustis Technologies, Inc. (NASDAQ:AKTS) posted its quarterly earnings results on Sunday, January, 31st. The technology company reported ($0.30) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.06. The technology company had revenue of $1.31 million for the quarter, compared to analyst estimates of $1.04 million. Akoustis Technologies had a negative trailing twelve-month return on equity of 72.62% and a negative net margin of 2,077.27%.
View Akoustis Technologies' earnings history.

Akoustis Technologies' stock was trading at $5.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AKTS stock has increased by 192.7% and is now trading at $15.54.
View which stocks have been most impacted by COVID-19.

5 brokers have issued twelve-month target prices for Akoustis Technologies' shares. Their forecasts range from $17.00 to $25.00. On average, they expect Akoustis Technologies' stock price to reach $20.20 in the next year. This suggests a possible upside of 30.0% from the stock's current price.
View analysts' price targets for Akoustis Technologies or view top-rated stocks among Wall Street analysts.

Some companies that are related to Akoustis Technologies include Avaya (AVYA), Infinera (INFN), Plantronics (PLT), Telkom SA SOC (TLKGY), NETGEAR (NTGR), AudioCodes (AUDC), ADTRAN (ADTN), Clearfield (CLFD), DZS (DZSI), Sunworks (SUNW), Franklin Wireless (FKWL), Zoom Telephonics (MINM), Zoom Telephonics (ZMTP), Sonim Technologies (SONM) and ClearOne (CLRO).
View all of AKTS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akoustis Technologies investors own include Inseego (INSG), NVIDIA (NVDA), Square (SQ), Editas Medicine (EDIT), Marvell Technology Group (MRVL), Alibaba Group (BABA), Invitae (NVTA), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP) and JD.com (JD).

Akoustis Technologies trades on the NASDAQ under the ticker symbol "AKTS."

Akoustis Technologies' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.23%), Handelsbanken Fonder AB (2.71%), Senvest Management LLC (2.38%), Needham Investment Management LLC (1.43%), Taylor Frigon Capital Management LLC (1.40%) and Handelsinvest Investeringsforvaltning (1.04%). Company insiders that own Akoustis Technologies stock include Arthur Geiss, David Aichele, Jeffrey B Shealy, Jeffrey Mcmahon, Kenneth Boller, Rohan Houlden, Steven Denbaars and Suzanne B Rudy.
View institutional ownership trends for Akoustis Technologies.

AKTS stock was sold by a variety of institutional investors in the last quarter, including North Run Capital LP, Millrace Asset Group Inc., Rovida Advisors Inc., Financial Advocates Investment Management, Mission Wealth Management LP, Oppenheimer & Co. Inc., Chartwell Investment Partners LLC, and Alliancebernstein L.P.. Company insiders that have sold Akoustis Technologies company stock in the last year include Arthur Geiss, David Aichele, Jeffrey B Shealy, Jeffrey Mcmahon, Kenneth Boller, Rohan Houlden, Steven Denbaars, and Suzanne B Rudy.
View insider buying and selling activity for Akoustis Technologies or view top insider-selling stocks.

AKTS stock was purchased by a variety of institutional investors in the last quarter, including Senvest Management LLC, Taylor Frigon Capital Management LLC, Handelsbanken Fonder AB, Handelsinvest Investeringsforvaltning, Squarepoint Ops LLC, Weil Company Inc., Benjamin F. Edwards & Company Inc., and Needham Investment Management LLC.
View insider buying and selling activity for Akoustis Technologies or or view top insider-buying stocks.

Shares of AKTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AKTS stock can currently be purchased for approximately $15.54.

Akoustis Technologies has a market capitalization of $658.79 million and generates $1.79 million in revenue each year. The technology company earns $-36,140,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

Akoustis Technologies employs 95 workers across the globe.

The official website for Akoustis Technologies is www.akoustis.com.

Akoustis Technologies is headquartered at 9805 NORTHCROSS CENTER COURT SUITE A, HUNTERSVILLE NC, 28078.

Akoustis Technologies' mailing address is 9805 NORTHCROSS CENTER COURT SUITE A, HUNTERSVILLE NC, 28078. The technology company can be reached via phone at 704-997-5735 or via email at [email protected]